Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.7.6 (
RNA polymerase
)
34,946
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The essential C17 subunit of yeast
RNA polymerase
(Pol) III interacts with Brf1, a component of TFIIIB, suggesting a role for C17 in the initiation step of transcription. The protein sequence of C17 (encoded by RPC17) is conserved from yeasts to humans. However, mammalian homologues of C17 (named
CGRP-RCP
) are known to be involved in a signal transduction pathway related to G protein-coupled receptors, not in transcription. In the present work, we first establish that human
CGRP-RCP
is the genuine orthologue of C17.
CGRP-RCP
was found to functionally replace C17 in Deltarpc17 yeast cells; the purified mutant Pol III contained
CGRP-RCP
and had a decreased specific activity but initiated faithfully. Furthermore,
CGRP-RCP
was identified by mass spectrometry in a highly purified human Pol III preparation. These results suggest that
CGRP-RCP
has a dual function in mammals. Next, we demonstrate by genetic and biochemical approaches that C17 forms with C25 (encoded by RPC25) a heterodimer akin to Rpb4/Rpb7 in Pol II. C17 and C25 were found to interact genetically in suppression screens and physically in coimmunopurification and two-hybrid experiments. Sequence analysis and molecular modeling indicated that the C17/C25 heterodimer likely adopts a structure similar to that of the archaeal RpoE/RpoF counterpart of the Rpb4/Rpb7 complex. These
RNA polymerase
subunits appear to have evolved to meet the distinct requirements of the multiple forms of RNA polymerases.
...
PMID:An Rpb4/Rpb7-like complex in yeast RNA polymerase III contains the orthologue of mammalian CGRP-RCP. 1248 73